ProBioGen AG and Life Technologies Corporation announce the launch of the new Freedom^TM CHO-S^TM Kit as the result of a successful co-development. The kit was built for developing stable high yield production cell lines in less than 4 months, and is based on Life Technologies' CHO-S^TM Cells. The Freedom^TM CHO-S^TM Kit platform enables end-users the cost- and time-efficient creation of stable cell lines for research and commercial purposes. The kit's applicability and efficiency was confirmed in several studies, in which antibody titers of 1 to 3 g/L have been obtained.

The kit is sold by Life Technologies.

About the Freedom^TM CHO-S^TM Kit
The Freedom^TM CHO-S^TM Kit includes all major components to complete the cell line development work flow: cGMP banked CHO-S^TM cells, a cloning vector for two genes, transfection reagent, competent cells, serum-free cell culture media and reagents. With this kit it is possible to go from transfection to lead clone in less than 4 months. Research use rights are granted upon kit purchase.

A full documentation package is provided as part of a commercial use license. The package includes the cell line's lineage as well as the history and the parental cGMP testing results.

About ProBioGen AG
ProBioGen is a renowned Contract Development and Manufacturing Organization (CDMO) and Technology Provider, focusing on cell line engineering, process development (upstream- and downstream) and GMP manufacturing of biopharmaceuticals. ProBioGen's royalty-free, fee-for service-based CHO platform is based on almost 20 years of experience in mammalian cell culture.

Combined with its innovative scientific excellence and strong intellectual property base, ProBioGen covers the entire drug development value chain, including regulatory support for IND-filing. All of ProBioGen's services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen was founded in 1994 and is located in Berlin, Germany.